<em>BRD</em>4沉默联合吉西他滨为治疗三阴性乳腺癌提供新的治疗方案

陈玉丽; 朱勤伟; 隋晓梅

doi:10.19401/j.cnki.1007-3639.2016.09.005

您当前的位置：

首页 >

文章列表页 >

BRD4沉默联合吉西他滨为治疗三阴性乳腺癌提供新的治疗方案

更新时间：2025-12-31

- BRD4沉默联合吉西他滨为治疗三阴性乳腺癌提供新的治疗方案
- BRD4 scilencing plus gemcitabine may be a novel therapy for triple-negative breast cancer
- 中国癌症杂志 2016年26卷第9期页码：750-755
- 作者机构：
  
  1. 潍坊医学院,山东,潍坊,261041
  2. 潍坊市中医院,山东,潍坊,261041
  3. 潍坊医学院附属医院放疗科,山东,潍坊,261042
- 作者简介：
- 基金信息：
  
  潍坊市卫生局科研立项项目(2014037)。
- DOI：10.19401/j.cnki.1007-3639.2016.09.005
  中图分类号：
- 网络出版：2016-10-26，
  
  纸质出版：2016-10-26
- 稿件说明：
移动端阅览
陈玉丽,朱勤伟,隋晓梅,等.

陈玉丽, 朱勤伟, 隋晓梅. BRD4 scilencing plus gemcitabine may be a novel therapy for triple-negative breast cancer[J]. China Oncology, 2016, 26(9): 750-755.
陈玉丽,朱勤伟,隋晓梅,等. DOI： 10.19401/j.cnki.1007-3639.2016.09.005.

陈玉丽, 朱勤伟, 隋晓梅. BRD4 scilencing plus gemcitabine may be a novel therapy for triple-negative breast cancer[J]. China Oncology, 2016, 26(9): 750-755. DOI： 10.19401/j.cnki.1007-3639.2016.09.005.

摘要

背景与目的：乳腺癌是女性发病率最高的恶性肿瘤，其发病率和死亡率逐渐上升，特别是三阴性乳腺癌(triple-negative breast cancer，TNBC)缺乏有效的治疗靶点，死亡率更高。在以往的研究中，BRD4在多种肿瘤的进展中起到重要的作用。该研究旨在研究BRD4在耐吉西他滨的TNBC中所起到的作用，联合BRD4沉默和吉西他滨治疗TNBC的效果。方法：分别应用反转录聚合酶链反应(reverse transcription polymerase chain reaction，RT-PCR)和蛋白［质］印迹法(Western blot)检测人乳腺癌细胞株MDA-MB-231和MDA-MB-453在吉西他滨治疗中表达变化。BRD4被shBRD4沉默后，通过体内和体外实验验证BRD4在耐药的TNBC中所起到的作用。结果：在TNBC中，BRD4在吉西他滨诱导后表达量明显的升高(P0.05)。沉默BRD4基因后，吉西他滨的半数抑制率明显降低，BRD4沉默联合吉西他滨使细胞的凋亡率明显升高(P0.05)；在体外实验中，BRD4沉默联合吉西他滨可以使肿瘤的生长速度明显降低(P0.05)。结论：BRD4在耐药的TNBC中起到重要的作用，BRD4沉默联合吉西他滨为治疗TNBC提供新的治疗方法。

Abstract

Background and purpose: Breast cancer has the highest morbidity and mortality rate in women worldwide. Triple-negative breast cancer (TNBC) has no specific target and has low survival rate. Recent studies have verified BRD4 could promote tumor progression. This study aimed to detect the expression level of BRD4 in TNBC after treatment with gemcitabine

and to reveal the effect of BRD4 silencing plus gemcitabine as a treatment for TNBC. Methods: The expression of BRD4 in TNBC cell lines treated with gemcitabine was detected by reverse transcription PCR (RT-PCR) and Western blot. The effect of BRD4 silencing plus gemcitabine in TNBC was illustrated in vitro and in vivo. Results: The expression of BRD4 in TNBC was significantly increased after treatment with gemcitabine. In vitro

BRD4 knockdown significantly lowered the IC50 value. The apoptotic rate of TNBC was significantly increased in the BRD4 silencing plus gemcitabine group compared to the other. The growth rate of tumor in vivo was significantly lowered in the BRD4 silencing plus gemcitabine group. Conclusion: BRD4 may play an important role in the drug resistance to gemcitabine in TNBC. BRD4 silencing plus gemcitabine may be a novel treatment strategy for TNBC.

关键词

Keywords

references

浏览量

2078

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

SERPINA3通过抑制铁死亡促进胰腺癌的恶性进展及吉西他滨耐药的机制研究

TIPE通过调控LDHA表达影响三阴性乳腺癌糖代谢重编程机制研究

三级淋巴结构异质性在三阴性乳腺癌新辅助治疗中的预测作用及免疫微环境特征的研究现状与展望

胰腺癌吉西他滨化疗耐药生物标志物—INPP4B的探索性研究

uPAR通过MAPK信号抑制细胞自噬促进胰腺癌增殖、侵袭及化疗抵抗的作用研究

BRD4沉默联合吉西他滨为治疗三阴性乳腺癌提供新的治疗方案

BRD4 scilencing plus gemcitabine may be a novel therapy for triple-negative breast cancer

DOI：10.19401/j.cnki.1007-3639.2016.09.005

摘要

Abstract

关键词

Keywords

references